Medical Company Secures FDA Approval For Neuropathic Pain Treatment

OKYO Pharma Receives FDA Approval for Groundbreaking Treatment in Neuropathic Corneal Pain.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant breakthrough for the medical community and patients suffering from neuropathic corneal pain, OKYO Pharma Corporation (LSE: OKYO) has received approval from the U.S. Food and Drug Administratio…